{"id":617660,"date":"2022-09-21T15:06:02","date_gmt":"2022-09-21T15:06:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=617660"},"modified":"2022-09-21T15:06:02","modified_gmt":"2022-09-21T15:06:02","slug":"lymphedema-market-to-exhibit-moderate-growth-rate-till-20222032-investigates-delveinsight-key-companies-herantis-pharma-puretech","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/lymphedema-market-to-exhibit-moderate-growth-rate-till-20222032-investigates-delveinsight-key-companies-herantis-pharma-puretech_617660.html","title":{"rendered":"Lymphedema Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies &#8211; Herantis Pharma, PureTech"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1663743968.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Lymphedema Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies - Herantis Pharma, PureTech \" src=\"https:\/\/www.abnewswire.com\/uploads\/1663743968.jpeg\" alt=\"Lymphedema Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies - Herantis Pharma, PureTech \" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u201cLymphedema Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Lymphedema, historical and forecasted epidemiology as well as the Lymphedema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\">The <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/lymphedema-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gprhttps:\/\/www.delveinsight.com\/report-store\/lymphedema-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Lymphedema market<\/a><\/strong> is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Lymphedema pipeline products will significantly revolutionize the Lymphedema market dynamics.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Lymphedema Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Lymphedema is the condition that may be caused in the body due to cancer and as a side effect of the cancer treatment. It occurs due to the buildup fluids in soft body tissues which leads to swelling in the organs, particularly limbs. Lymphedema can lead to psychological, physical and social problems in patients.<\/p>\n<p style=\"text-align: justify;\">Lymphedema symptoms include hair loss, troubled sleep, a burning sensation in legs, itching in toes and legs, skin thickening, trouble moving arms or legs, heaviness in arms and legs, swelling in arms and legs, which may include toes and fingers. Lymphedema diagnosis may be based on past cancer history of the patient. Test such as Doppler ultrasound, CT scan, MRI scan, and radio nuclide imaging of the lymphatic system may be carried out.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Lymphedema Market Report:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Lymphedema market size is anticipated to grow with a significant <strong>CAGR<\/strong> during the study period <strong>(2019-2032)<\/strong>&nbsp;<\/li>\n<li>In a study by <strong>Brayn C et al.<\/strong>, Lymphedema may affect as many as <strong>140&ndash;250 million<\/strong> persons worldwide. Primary lymphedema is rare, affecting <strong>1 in 100,000<\/strong> individuals. Secondary lymphedema is the most common cause of the disease and affects approximately <strong>1 in 1000&nbsp;<\/strong><\/li>\n<li>As per Schook et al., the pediatric population onset occurs in infancy <strong>(49.2%),<\/strong> childhood <strong>(9.5 %)<\/strong>, or adolescence <strong>(41.3%)&nbsp;<\/strong><\/li>\n<li>Among the <strong>EU-5 countries<\/strong>, France accounts for highest market size for lymphedema followed by Germany, UK, Italy and Spain&nbsp;<\/li>\n<li><strong>Key Lymphedema Companies:<\/strong> Herantis Pharma, PureTech, and others&nbsp;<\/li>\n<li><strong>Key Lymphedema Therapies:<\/strong> Lymfactin, LYT-100, and others&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/lymphedema-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Lymphedema Market Report<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key benefits of the Lymphedema Market report:<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Lymphedema market report covers a descriptive overview and comprehensive insight of the Lymphedema Epidemiology and Lymphedema market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/li>\n<li>The Lymphedema market report provides insights on the current and emerging therapies.<\/li>\n<li>Lymphedema market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n<li>The Lymphedema market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Lymphedema market.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Lymphedema market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/lymphedema-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Lymphedema market forecast<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Lymphedema Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Lymphedema market report proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalence of Lymphedema<\/li>\n<li>Prevalent Cases of Lymphedema by severity<\/li>\n<li>Gender-specific Prevalence of Lymphedema<\/li>\n<li>Diagnosed Cases of Episodic and Chronic Lymphedema&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Lymphedema Market &nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The dynamics of the Lymphedema market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Lymphedema epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/lymphedema-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Lymphedema Epidemiological Insights<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Lymphedema Market Strengths<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Lymphedema is a complex disorder, efforts have been made by researchers and scientific professionals to improve the understanding of the pathogenesis and diagnosis of this condition<\/li>\n<li>Treatment of Lymphedema has improved significantly in recent years with the availability of several safe and effective therapies. Several consensus guidelines have been created to further assist in the management of Lymphedema patients<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Lymphedema Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Lymfactin:<\/strong> Herantis Pharma<\/li>\n<li><strong>LYT-100:<\/strong> PureTech<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Lymphedema Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period: 2019&ndash;2032<\/strong><\/li>\n<li><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li><strong>Key Lymphedema Companies:<\/strong> Herantis Pharma, PureTech, and others<\/li>\n<li><strong>Key Lymphedema Therapies:<\/strong> Lymfactin, LYT-100, and others<\/li>\n<li><strong>Lymphedema Therapeutic Assessment:<\/strong> Lymphedema current marketed and Lymphedema emerging therapies<\/li>\n<li><strong>Lymphedema Market Dynamics:<\/strong>&nbsp; Lymphedema market drivers and barriers&nbsp;<\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li><strong>Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Lymphedema&nbsp; Market Access and Reimbursement&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Lymphedema Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Challenges in Lymphedema diagnoses<\/li>\n<li>Development of novel Lymphedema therapies<\/li>\n<li>Limitations in gene therapy<\/li>\n<li>Poor disease understanding<\/li>\n<li>Clinical biomarkers<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Lymphedema Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Lymphedema<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Lymphedema<\/p>\n<p style=\"text-align: justify;\">4. Lymphedema Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Lymphedema Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Lymphedema Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Lymphedema Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Lymphedema&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Lymphedema Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Lymphedema Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Lymphedema Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Lymphedema Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Lymphedema Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. Lymphedema Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Lymphedema Market drivers<\/p>\n<p style=\"text-align: justify;\">16. Lymphedema Market barriers<\/p>\n<p style=\"text-align: justify;\">17.&nbsp; Lymphedema Appendix<\/p>\n<p style=\"text-align: justify;\">18. Lymphedema Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Lymphedema treatment, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/lymphedema-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Lymphedema Medications<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=lymphedema-market-to-exhibit-moderate-growth-rate-till-20222032-investigates-delveinsight-key-companies-herantis-pharma-puretech\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=lymphedema-market-to-exhibit-moderate-growth-rate-till-20222032-investigates-delveinsight-key-companies-herantis-pharma-puretech\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight\u2019s \u201cLymphedema Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Lymphedema, historical and forecasted epidemiology as well as the Lymphedema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/lymphedema-market-to-exhibit-moderate-growth-rate-till-20222032-investigates-delveinsight-key-companies-herantis-pharma-puretech_617660.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[408,405,417,406,423],"tags":[],"class_list":["post-617660","post","type-post","status-publish","format-standard","hentry","category-Electronics-Semiconductors","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/617660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=617660"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/617660\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=617660"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=617660"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=617660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}